Background: Anti-HER2 therapies are associated with a risk of increased cardiac toxicity, particularly when part of anthracycline-containing regimens. We report cardiac safety of pertuzumab, trastuzumab, and chemotherapy in the neoadjuvant treatment of HER2-positive early breast cancer.
Introduction
HER2 is overexpressed/gene-amplified in 15%-20% of breast cancers (BC) [1] and associated with poor prognoses. Trastuzumab plus chemotherapy has progression-free survival (PFS)/overall survival benefits in HER2-positive metastatic BC [2] . Pertuzumab, trastuzumab, and docetaxel showed further benefits, with significantly improved PFS/overall survival versus placebo, trastuzumab, and docetaxel [3, 4] . Pertuzumab, trastuzumab, and docetaxel is efficacious in the neoadjuvant setting, with a 17.8% increase in pathologic complete response (pCR, ypT0/is ypN0) rates versus trastuzumab plus docetaxel in NeoSphere [5] , and similar benefits in additional studies [6, 7] . Exploratory PFS and disease-free survival results from NeoSphere and TRYPHAENA supported pCR benefits [8, 9] .
Trastuzumab is associated with a risk of cardiac toxicity, particularly when given with anthracyclines. In BCIRG006 (trastuzumab plus chemotherapy in early BC [EBC] ), incidences of congestive heart failure were 2.0% and 0.4% in the anthracycline-and nonanthracycline arms, respectively [10] . Higher cardiac event rates with trastuzumab were also seen in studies of anthracyclinecontaining regimens 6 trastuzumab [11, 12] . Therefore, cardiac safety within the context of chemotherapy regimen is an important consideration.
In CLEOPATRA, there was no increased cardiac risk (heart failure) with pertuzumab [3, 4] ; no additional/long-term cardiotoxicities were associated with combination therapy in NeoSphere [8] . Pertuzumab plus trastuzumab was associated with little additional toxicity in NeoSphere [5] and TRYPHAENA [6] (mainly increased incidence, but not severity, of diarrhea, rash, and mucositis); there was little impact on doses received, dose interruptions/modifications/discontinuations, or treatment-related mortality [5, 6] . NCCN guidelines recommend pertuzumab-containing regimens for HER2-positive BC. While pertuzumab plus trastuzumab has an acceptable safety profile in combination with epirubicin, when BERENICE was designed there were no doxorubicin data, and limited data on pertuzumab, trastuzumab, and paclitaxel in EBC (GeparSepto assessed paclitaxel/nab-paclitaxel, pertuzumab, and trastuzumab followed by epirubicin and cyclophosphamide [7] ).
The ongoing BERENICE study (NCT02132949) was designed to evaluate the cardiac safety of two neoadjuvant anthracycline-/taxane-based regimens with pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive BC, and normal cardiac function. We present the primary analysis: cardiac safety during the neoadjuvant period (clinical cutoff at the date of last patient's breast surgery).
Patients and methods
BERENICE is a nonrandomized, phase II, open-label, multicenter, multinational cardiac safety study across 75 centers/12 countries in full accordance with Good Clinical Practice guidelines/Declaration of Helsinki.
All participants provided written informed consent. The protocol and modifications were approved by independent ethics committees.
Procedures
Eligible patients were investigator-assigned to cohorts (Figure 1 ). In the neoadjuvant period, cohort A patients received four q2w cycles of dosedense doxorubicin plus cyclophosphamide (ddAC) followed 2 weeks later by 12 qw paclitaxel injections, while cohort B patients received four q3w cycles of fluorouracil, epirubicin, and cyclophosphamide then four q3w cycles of docetaxel. In both cohorts, four q3w cycles of trastuzumab and pertuzumab were started with taxane therapy and continued in the adjuvant setting (up to 13 cycles to complete 1 year of treatment). Surgery was scheduled after eight cycles of preoperative therapy. All study drugs were given intravenously. See supplementary data, available at Annals of Oncology online, for dose modification, and supplementary Figure S1 , available at Annals of Oncology online, for management of HER2-targeted treatment based on left ventricular ejection fraction (LVEF) decreases. Optional granulocyte-colony stimulating factor support could be given per local practice. Patients could withdraw consent at any time or be withdrawn by the investigator/sponsor for safety reasons, if in the patient's best interests, or for noncompliance with the protocol.
Assessments
The primary end point was cardiac safety of neoadjuvant treatment assessed by incidence of New York Heart Association (NYHA) class III and IV heart failure and LVEF declines (10 percentage-points from baseline and to a value of <50% [symptomatic and asymptomatic]) by echocardiography or multiple-gated acquisition scan. LVEF assessments were conducted at screening/baseline and within 3 days before day 1 of cycles 5 and 7 during the neoadjuvant period. Adverse events (AEs) were assessed throughout the treatment period per National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE) V4.0. Safety data are regularly reviewed by the Steering Committee (sponsor representatives, investigators, plus an independent cardiology expert). Tumors were assessed clinically at screening/baseline and at each cycle during neoadjuvant treatment. Patients are also assessed for recurrence at cycles 9, 13, 17, and 21 during adjuvant treatment, and at study completion/termination visits, per local practice. Secondary end points included general safety during the neoadjuvant period (including incidence and severity of AEs/serious AEs; laboratory test anomalies) and all efficacy end points. The main efficacy end point was pCR in the breast and lymph nodes (ypT0/is ypN0; total pCR). pCR assessments were reviewed by an external pathology expert. Exploratory efficacy end points included local pathologist-assessed pCR rate and rate by major intrinsic BC subtype. To classify patients by intrinsic BC subtype, gene expression analyses were carried out by applying the Nanostring nCounter platform. Within the set of genes analyzed, the panel of genes required to assess the intrinsic BC subtypes as published by Parker et al was included [13] . The PAM50 subtype prediction to describe the major intrinsic subtypes (HER2-enriched, luminal A, luminal B, and basal-like) was carried out using the random-forest-based classifier described by Wilson et al [14] . Further end point details are presented in the supplementary data, available at Annals of Oncology online.
Safety was assessed in all patients who received 1 dose of study medication; pCR, in the intention-to-treat population.
Statistical methods
No formal sample size calculation/statistical hypothesis testing was performed. Results were summarized descriptively. Exact Clopper-Pearson 95% CIs of expected rates (NYHA class III/IV heart failure rate <3% and LVEF decline rate of 6%) [5, 6] were used to evaluate cardiac safety. Demographics/baseline characteristics were similar in each cohort (Table 1) . Treatment exposure during the neoadjuvant period is shown in supplementary Table S1 , available at Annals of Oncology online.
Results

Population
Incidence of NYHA class III and IV heart failure Three patients (1.5%) in cohort A experienced four NYHA class III/IV heart failure events ( Table 2) . One patient experienced two events (one class III and one class IV); due to the close chronology, Steering Committee members considered that these could represent continuation of one event. All occurred during neoadjuvant HER2 antibody treatment and all patients discontinued treatment. Recoveries were recorded for 2/4 events (the patient with two events recovered from the class IV event only). No patient in cohort B experienced any events.
Incidence of LVEF declines
Thirteen patients (6.5%) in cohort A and four (2.0%) in cohort B experienced 1 LVEF decline (Table 2) . Patients with a decline should have had treatment withheld and a repeat evaluation 3 weeks later. Confirmed declines (2 consecutive declines during the neoadjuvant period) were observed in two (1.0%) patients in cohort A and one (0.5%) in cohort B; all during neoadjuvant HER2-targeted therapy. Declines in the neoadjuvant period were generally reversible in most patients at the time of analysis, often with recovery by next assessment.
General safety
The most common AEs (any-grade) during the neoadjuvant period were nausea, diarrhea, and alopecia (Table 3) . The most common grade 3-4 AEs were blood and lymphatic system disorders, with febrile neutropenia the most common event, followed by neutropenia (Table 3 ). This was in keeping with the higher proportion of patients who received optional prophylactic bone marrow support in cohort A. Neutropenia recorded as "neutrophil count decreased" was reported in 9 patients (4.5%) in cohort A and 12 (6.1%) in cohort B. No grade 5 AEs were Pertuzumab q3w ×13 (420 mg)
Trastuzumab q3w ×13 (6 mg/kg) Figure 1 . Study design. BC, breast cancer; ddAC, dose-dense doxorubicin plus cyclophosphamide; ECOG, Eastern Cooperative Oncology Group; FEC, fluorouracil, epirubicin, and cyclophosphamide; HR, hormone receptor; LVEF, left ventricular ejection fraction; q2w, every 2 weeks; q3w, every 3 weeks; qw, every week. Only one cohort was opened at a time at any given site, and was defined before any patients were enrolled at that site. Investigator choice of cohort was based on local/regional practice.
reported. The most common serious AEs were febrile neutropenia and diarrhea. Ten patients (5.1%) in cohort B experienced grade 3-4 stomatitis (no cases were reported in cohort A). The most common reason for pertuzumab/trastuzumab discontinuation was ejection fraction decline (including one patient who discontinued but did not have a confirmed decline).
Efficacy pCR rates were 61.8% (95% CI 54.7% to 68.6%) and 60.7% (95% CI 53.6% to 67.5%) in cohorts A and B, respectively, and higher Patients were classified by intrinsic BC subtype using gene expression analyses carried out by applying the Nanostring nCounter platform and the PAM50 subtype prediction used to describe the major intrinsic subtypes (see supplementary data, available at Annals of Oncology online). e The statistical model applied did not allow categorization into any of the subgroups. in hormone receptor (HR)-negative versus HR-positive disease (Figure 2A) .
Local pathologist-assessed rates were 63.8% (95% CI 56.7% to 70.5%) in cohort A and 61.2% (95% CI 54.1% to 68.0%) in cohort B, including five patients in cohort A and four in cohort B with nodal stage NX. Of these, five patients did not have nodes assessed at surgery but were considered by the local pathologist to have achieved pCR.
Most patients had HER2-enriched BC (Table 1) , and the highest pCR rate was observed in this group (75.0% in cohort A and 73.7% in cohort B; Figure 2B ). The pCR rate was similar in luminal A and B groups across both cohorts ( Figure 2B ).
Discussion
The primary objective of BERENICE was to evaluate cardiac safety of trastuzumab, pertuzumab, and eight cycles of neoadjuvant chemotherapy (four anthracycline-based followed by four of dual HER2-targeted therapy plus taxane).
Overall incidence of NYHA class III/IV heart failure during neoadjuvant treatment was low and consistent with TRYPHAENA [6] . Notably, BERENICE included a longer neoadjuvant period (eight versus six chemotherapy cycles) [6] .
General safety was consistent with anticipated toxicity profiles of these regimens. Incidence of diarrhea associated with the taxane period was lower in cohort A; however, other reports have shown no difference in rates across taxanes when given with pertuzumab and trastuzumab [15] . Diarrhea was mostly low-grade, and only one patient (cohort B), discontinued pertuzumab/trastuzumab as a result. pCR rates were high in both cohorts and consistent with previous reports [5, 6] . Previous studies have reported pCR rates of 22%-64% for combinations of HER2-targeted therapy plus chemotherapy [5] [6] [7] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] . The high rate in HR-negative disease was consistent with data on trastuzumab plus pertuzumab 6 taxanes [29] . Lower rates in HR-positive disease were consistent with the lower rates observed in luminal A and B subtypes. The high pCR rate in the HER2-enriched subtype was consistent with data demonstrating that this subtype could identify patients who would most likely benefit from dual HER2-blockade [30] . Our distributions of relevant intrinsic subtypes (HER2-enriched and luminal A) are also broadly reflective of those reported in a HER2-positive population [31] . Patients will be followed for long-term efficacy outcomes.
BERENICE has limitations due to its design. As it is nonrandomized, the chemotherapy backbone's contribution to the data cannot be assessed. No control arm also means that the impact of pertuzumab alone on the safety/efficacy of the regimen cannot be assessed.
The safety/efficacy of pertuzumab plus trastuzumab and chemotherapy versus placebo plus trastuzumab and chemotherapy in the adjuvant setting was recently reported in the APHINITY trial, where pertuzumab significantly improved invasive disease-free survival with no new safety signals being identified [32] . BERENICE, KRISTINE [16] , and PEONY (NCT02586025) will evaluate pertuzumab plus trastuzumab treatment continuing from the neoadjuvant into the adjuvant setting. These trials will assess 1 year of dual HER2-targeted antibody therapy in EBC, spanning the neoadjuvant and/or adjuvant periods.
Conclusion
Treatment with pertuzumab, trastuzumab, and common anthracycline-containing chemotherapy regimens for the neoadjuvant treatment of EBC resulted in cardiac and general safety profiles, and pCR rates, consistent with prior pertuzumab studies. This is the first study to investigate ddAC followed by paclitaxel with pertuzumab and trastuzumab in the neoadjuvant setting. The safety profiles and high pCR rates in both cohorts support the use of pertuzumab and trastuzumab with a taxane following doxorubicin-or epirubicin-based chemotherapy in the neoadjuvant setting. Figure 2 . pCR (ypT0/is ypN0) (A) in the intention-to-treat (ITT) population and (B) by intrinsic breast cancer subtype. a D, docetaxel; ddAC, dose-dense doxorubicin plus cyclophosphamide; FEC, fluorouracil, epirubicin, and cyclophosphamide; H, trastuzumab; HR, hormone receptor; P, pertuzumab; pCR, pathologic complete response; T, paclitaxel. Six patients in cohort A and two in cohort B had missing central HR assessments.
a Patients were classified by intrinsic BC subtype using gene expression analyses carried out by applying the Nanostring nCounter platform and the PAM50 subtype prediction used to describe the major intrinsic subtypes (see supplementary data, available at Annals of Oncology online). b The statistical model applied did not allow categorization into any of the subgroups. Technical failure (assay failure or failure to extract RNA).
